• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Respiratory Society (ERS) - 34th Annual Congress

September 7 - 11, 2024

  1. FASENRA (benralizumab)
  2. TEZSPIRE (tezepelumab)
  3. NOVELTY
  4. PRECISION
  5. Tozorakimab

PDF

Baseline characteristics of patients with severe eosinophilic asthma treated with benralizumab who reduced to anti-inflammatory reliever only vs high-, medium- or low-dose inhaled corticosteroid/formoterol: SHAMAL post-hoc analysis

PDF

Early and continued asthma control improvement in patients with severe eosinophilic asthma over 1 year post benralizumab initiation: XALOC-2 real-world evidence programme

PDF

Clinical remission by BMI in patients with severe eosinophilic asthma over 1 year post benralizumab initiation: XALOC-2 real-world evidence programme

pdf

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis

PDF

Factors influencing lung function changes when inhaled corticosteroid/formoterol is reduced in patients with severe eosinophilic asthma treated with benralizumab

PDF

Serum RNASE3 and TREM2 biomarker set predicts clinical response to benralizumab in nasal polyps

PDF

Treatment patterns for eosinophilic granulomatosis with polyangiitis (EGPA): A retrospective observational cohort study in England

PDF

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab

PDF

Effect of treatment with benralizumab or mepolizumab on the serum proteome in eosinophilic granulomatosis with polyangiitis

PDF

Effect of Benralizumab treatment related immune modulation on COPD airway microbiome

PDF

Benralizumab reduces eosinophils and ANCA in sputum in eosinophilic granulomatosis with polyangiitis

PDF

Pharmacokinetics, pharmacodynamics and safety of tezepelumab in children with asthma

PDF

Biomarkers and phenotyping: a holistic approach to asthma treatment with tezepelumab

PDF

ARRIVAL: a phase 3b study to assess potential for tezepelumab to reduce maintenance inhaled therapy and induce remission in patients with severe asthma

PDF

Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE)

PDF

Evaluating the association of persistent or single-time point frequent productive cough with 12-month exacerbation rate in asthma and/or COPD

PDF

Characteristics of patient-reported worsenings of asthma and/or COPD and concordance with physician-reported exacerbations

PDF

The NOVELTY nasal transcriptome identifies mechanisms in asthma and COPD exacerbators

PDF

The nasal transcriptome reflects clinically relevant disease activity in NOVELTY, with a different signal in asthma and in COPD

PDF

Comparison of asthma assessment tools to minimize overestimation of control

PDF

Healthcare resource utilisation and cost one year after hospitalisation among patients hospitalised with viral lower respiratory tract disease: a descriptive US claims analysis

PDF

Exacerbation and mortality in COPD patients on triple inhaler and at high exacerbation risk

PDF

Healthcare resource use and cost one year after hospitalisation among patients admitted with viral lower respiratory tract disease by viral aetiology: a descriptive US claims analysis

PDF

Clinical characteristics of patients one year after hospitalisation for viral lower respiratory tract disease by viral aetiology: A descriptive US claims analysis

PDF

IL-33 signalling pathway biomarkers in severe viral lower respiratory tract disease: interim results from the prospective, observational UNIVERSAL study

PDF

Characteristics of exacerbating COPD patients with productive cough and on inhaled triple therapy, by smoking status: A real-world multi-country study

PDF

Perception of COPD control by physicians managing symptomatic exacerbating patients receiving inhaled triple therapy: a real-world multicountry 2022 survey

PDF

FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD

PDF

Clinical characteristics of patients one year after hospitalisation for viral lower respiratory tract disease: A descriptive US claims analysis

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice